Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral lefamulin versus oral moxifloxacin for community-acquired bacterial pneumonia
2015-004782-92Phase 3Completed
- Sponsor
- Nabriva Therapeutics plc
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lefamulin in community acquired pneumonia (CAP) (2 arms), sponsored by Nabriva Therapeutics plc. Primary endpoint: Early Clinical Response. Started Jun 2016; status: completed.
02
Drugs
lefamulin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2015-004782-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004782-92.